The diagnosis and treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease and chronic bronchitis

Journal of the American Geriatrics Society

Volumn 58, Issue 3, 2010, Pages 570-579

  Albertson, Timothy E ^a,b   Louie, Samuel ^a,b   Chan, Andrew L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

AECB; Antibiotics; Bronchiectasis; Bronchitis; COPD; Elderly patients

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMINOPHYLLINE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA LACTAM ANTIBIOTIC; BRONCHODILATING AGENT; CEPHALOSPORIN; CIPROFLOXACIN; CORTICOSTEROID; COTRIMAZINE; COTRIMOXAZOLE; DOXYCYCLINE; GEMIFLOXACIN; IMMUNOGLOBULIN G; IPRATROPIUM BROMIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PIVAMPICILLIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; TRIMETHOPRIM;

ACUTE EXACERBATION CHRONIC BRONCHITIS; ACUTE EXACERBATION CHRONIC OBSTRUCTIVE LUNG DISEASE; AGING; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; BRONCHIECTASIS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; ENTEROBACTER; HAEMOPHILUS INFLUENZAE; HUMAN; KLEBSIELLA PNEUMONIAE; MORAXELLA CATARRHALIS; MYCOBACTERIUM; NONHUMAN; OXYGEN THERAPY; PENICILLIN RESISTANT STREPTOCOCCUS PNEUMONIAE; PROTEUS; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; VACCINATION;

ACUTE DISEASE; AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BRONCHIECTASIS; BRONCHITIS, CHRONIC; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

EID: 77949343076     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2010.02741.x     Document Type: Review

References (76)

1. Celli BR, Snider GL, Heffner J et al. ATS guidelines. Diagnosis and care of patients with COPD: I. definitions epidemiology; pathophysiology; diagnosis and prognosis. Am J Respir Crit Care Med 1995;152:S77-S120.
2. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009;4:435-459.
3. Balter MS, La Forge J, Low DE et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003;10(Suppl B): 3B-32B.
4. Meyer KC. Lung infections and aging. Ageing Res Rev 2004;3:55-67.
5. Meyer KC. Aging. Proc Am Thorac Soc 2005;2:433-439.
6. Hayes D Jr., Meyer KC. Acute exacerbations of chronic bronchitis in elderly patients: Pathogenesis, diagnosis and management. Drugs Aging 2007;24:555-572.
7. Miravitlles M. Do we need new antibiotics for treating exacerbations of COPD? Ther Adv Respir Dis 2007;1:61-76.
8. Lopez AD, Shibuya K, Rao C et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J 2006;27:397-412.
9. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study. Lancet 2007;370:741-750.
10. Medbo A, Melbye H. Lung function testing in the elderly-can we still use FEV1/FVC<70% as a criterion of COPD? Respir Med 2007;101:1097-1105.
11. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009;135:173-180.
12. Pauwels R, Calverley P, Buist AS et al. COPD exacerbations: The importance of a standard definition. Respir Med 2004;98:99-107.
13. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117:398S-401S.
14. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:554-564.
15. Murphy TF, Sethi S. Chronic obstructive pulmonary disease: Role of bacteria and guide to antibacterial selection in the older patient. Drugs Aging 2002;19:761-775.
16. Murphy TF. The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis 2006;19:225-230.
17. Mapel DW, Robinson SB, Dastani HB et al. The direct medical costs of undiagnosed chronic obstructive pulmonary disease. Value Health 2008;11: 628-636.
18. Sethi S, Evans N, Grant BJ et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-471.
19. Burgel PR, Nesme-Meyer P, Chanez P et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009;135:975-982.
20. Brunton S, Carmichael BP, Colgan R et al. Acute exacerbation of chronic bronchitis: A primary care consensus guideline. Am J Manage Care 2004;10:689-696.
21. Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106: 196-204.
22. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273: 957-960.
23. Halbert RJ, Isonaka S, George D et al. Interpreting COPD prevalence estimates: What is the true burden of disease? Chest 2003;123:1684-1692.
24. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999;21:576-591.
25. Hurd S. The impact of COPD on lung health worldwide: Epidemiology and incidence. Chest 2000;117:1S-4S.
26. Connolly MJ, Lowe D, Anstey K et al. Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: Effect of age related factors and service organisation. Thorax 2006;61:843-848.
27. Roberts CM, Lowe D, Bucknall CE et al. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002;57:137-141.
28. McGuire A, Irwin DE, Fenn P et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health 2001;4:370-375.
29. O'Donnell AE. Bronchiectasis. Chest 2008;134:815-823.
30. Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr Opin Pulmon Med 2008;14:595-599.
31. Patel IS, Vlahos I, Wilkinson TM et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:400-407.
32. Weycker D, Edelsberg J, Oster G et al. Prevalence and economic burden of bronchiectasis. Clin Pulmon Med 2005;12:205.
33. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: A state-of-the-art review. Clin Microbiol Rev 2001;14:336-363.
34. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000;117:380S-385S.
35. Soler N, Torres A, Ewig S et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998;157:1498-1505.
36. Eller J, Ede A, Schaberg T et al. Infective exacerbations of chronic bronchitis: Relation between bacteriologic etiology and lung function. Chest 1998;113:1542-1548.
37. Rennie RP, Ibrahim KH. Antimicrobial resistance in Haemophilus influenzae: how can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program. Clin Infect Dis 2005;41(Suppl 4):S234-S238.
38. Hoban DJ, Doern GV, Fluit AC et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRYAntimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(Suppl 2):S81-S93.
39. Neralla S, Meyer KC. Drug treatment of pneumococcal pneumonia in the elderly. Drugs Aging 2004;21:851-864.
40. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005;41: 118-121.
41. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-ediated quinolone resistance. Lancet Infect Dis 2006;6:629-640.
42. Caramori G, Adcock IM, Papi A. Clinical definition of COPD exacerbations and classification of their severity. South Med J 2009;102:277.
43. From the Global Strategy for the Diagnosis MaPoC, Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) [on-line]. Available at http://wwwgoldcopdorg, 2007 Accessed November 1, 2009.
44. Hayes D Jr., Meyer KC. Acute exacerbations of chronic bronchitis in elderly patients: Pathogenesis, diagnosis and management. Drugs Aging 2007;24: 555-572.
45. Blasi F, Ewig S, Torres A et al. A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis. Pulm Pharmacol Ther 2006;19:361-369.
46. Martinez FJ, Grossman RF, Zadeikis N et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: The role of levofloxacin 750 mg. Eur Respir J 2005;25:1001-1010.
47. Bourbeau J, Marciniuk D, Balter M et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J 2008;15:1A.
48. MacNee W. Acute exacerbations of COPD. Swiss Med Wkly 2003;133: 247-257.
49. McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2002: CD003900.
50. Dzierba AL, Jelic S. Chronic obstructive pulmonary disease in the elderly: An update on pharmacological management. Drugs Aging 2009;26:447-456.
51. Bellia V, Battaglia S, Matera MG et al. The use of bronchodilators in the treatment of airway obstruction in elderly patients. Pulm Pharmacol Ther 2006;19:311-319.
52. Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: A systematic review and metaanalysis. Chest 2008;133:756-766.
53. Sin DD, McAlister FA, Man SF et al. Contemporary management of chronic obstructive pulmonary disease: Scientific review. JAMA 2003;290:2301-2312.
54. O'Donnell DE, Hernandez P, Kaplan A et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J 2008; 15(Suppl A):1A-8A.
55. El Moussaoui R, Roede BM, Speelman P et al. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: A meta-analysis of double-blind studies. Thorax 2008;63:415-422.
56. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3:331-350.
57. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A et al Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2006: CD004403.
58. Bont J, Hak E, Birkhoff CE et al. Is co-morbidity taken into account in the antibiotic management of elderly patients with acute bronchitis and COPD exacerbations? Fam Pract 2007;24:317-322.
59. Dimopoulos G, Siempos II, Korbila IP et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: A metaanalysis of randomized controlled trials. Chest 2007;132:447-455.
60. Siempos II, Dimopoulos G, Korbila IP et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: A meta-analysis. Eur Respir J 2007;29:1127-1137.
61. Korbila IP, Manta KG, Siempos II et al. Penicillins vs trimethoprim-based regimens for acute bacterial exacerbations of chronic bronchitis: Meta-analysis of randomized controlled trials. Can Fam Phys 2009;55:60.
62. Falagas ME, Avgeri SG, Matthaiou DK et al. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: A meta-analysis. J Antimicrob Chemother 2008;62:442-450.
63. Milstone AP. Use of azithromycin in the treatment of acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2008;3:515.
64. Sin DD, Tu JV. Outpatient antibiotic therapy and short term mortality in elderly patients with chronic obstructive pulmonary disease. Can Resp J 2000;7:466-475.
65. Wilson R, Allegra L, Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004;125:953-964.
66. Wilson R, Langan C, Ball P et al. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir Med 2003;97:242-249.
67. Anzueto A, Fisher CL Jr., Busman T et al. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin Ther 2001; 23:72-86.
68. Llor C, Hernandez S, Ribas A et al. Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care. Int J Chron Obstruct Pulmon Dis 2009;4:45-53.
69. Petitpretz P, Chone C, Tremolieres F. Levofloxacin 500mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: Clinical efficacy and exacerbation-free interval. Int J Antimicrob Agents 2007;30:52-59.
70. Amsden GW, Baird IM, Simon S et al. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003;123:772-777.
71. Grossman RF, Ambrusz ME, Fisher AC et al. Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: A post hoc analysis of data from severely ill patients. Clin Ther 2006;28:1175-1180.
72. Urueta-Robledo J, Ariza H, Jardim JR et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: The Latin American Cohort. Respir Med 2006;100:1504-1511.
73. Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2004;23:129-137.
74. Zervos M, Martinez FJ, Amsden GW et al. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int J Antimicrob Agents 2007;29: 56-61.
75. Grassi C, Casali L, Curti E et al. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother 2002;14:597-608.
76. Schaberg T, Ballin I, Huchon G et al. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 2001;29:314-328.